What is NDA short for in the context of drug regulation?

• A. New Drug Application (NDA)
• B. Placebo
• C. IND
• D. Phase I Testing

Answer: (A)

The main idea here is understanding what regulatory submissions signal approval to bring a drug to market. NDA stands for New Drug Application, and it’s the formal package a sponsor submits to the FDA after completing preclinical and clinical testing. This comprehensive submission includes safety and efficacy data from trials, manufacturing details and quality controls, labeling, and plans for post‑marketing monitoring. The FDA reviews the NDA to determine if the drug’s benefits justify the risks and whether it can be safely manufactured and marketed.

This differs from an Investigational New Drug (IND) application, which is what allows starting human trials, not marketing authorization. Phase I testing is simply an early clinical trial phase to assess safety and dosing, not a regulatory approval document. A placebo is a nonactive substance used as a control in trials, not a regulatory submission.